CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE MKT: PTN) announced that after the closing
of its licensing agreement with AMAG Pharmaceuticals, Inc. (Nasdaq:
AMAG) for exclusive North American rights to develop and
commercialize Rekynda™ (bremelanotide), an investigational product
designed for on-demand treatment of hypoactive sexual desire
disorder (HSDD) in pre-menopausal women, it will hold a conference
call and audio webcast to discuss the licensing agreement and next
steps for Palatin. The licensing agreement is expected to
close in the first quarter of calendar year 2017.
The call will discuss Palatin's role in further development and
regulatory approval of Rekynda, and potential licensing
transactions outside North America. The call will also
discuss Palatin's anticipated next steps in its other drug
development programs, including its melanocortin receptor-1
agonist peptides for treatment of inflammatory and dermatologic
disease indications, melanocortin receptor-4 agonist compounds for
treatment of obesity and diabetes, and natriuretic peptide
receptor-A agonist compounds for treatment of cardiovascular and
pulmonary indications.
Palatin will announce the date and time of its conference call
and audio webcast shortly after closing of the licensing agreement
with AMAG Pharmaceuticals.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential. Palatin's strategy is to develop products and
then form marketing collaborations with industry leaders in order
to maximize their commercial potential. For additional information
regarding Palatin, please visit Palatin's website
at http://www.palatin.com.
Rekynda™ is a trademark of Palatin Technologies, Inc.
Forward-Looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about actions by third
parties, clinical trial results, potential actions by regulatory
agencies, financings, projected operations and other statements
containing the words "anticipate," "believe," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities
Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that could cause Palatin's
actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/palatin-technologies-to-hold-call-following-closing-of-licensing-agreement-for-north-american-rights-to-rekynda-300388974.html
SOURCE Palatin Technologies, Inc.